FDA Describes How it Selects Manufacturing Sites For Inspections

It is no secret that FDA cannot inspect all drug manufacturing sites, so it prioritizes certain kind of sites based on internal selection criteria. But till yesterday, the details of the selection process were not publicly known. Yesterday FDA released its internal policy for selecting and prioritizing drug manufacturing sites for inspections providing a new … Read more

FDA Initiative For Innovative Clinical Trial Designs To Expedite Product Approval 

This week FDA announced a new initiative to encourage disruptive clinical trial designs aiming to expedite market approval of promising drugs and biologics. Several of these trial designs have been proposed in the recent years, mostly for products intended to treat cancers. The new initiative, called Complex Innovative Trial Design (CID) expands innovative trial designs … Read more

FDA’s Warns Online Pharmacies Selling Drugs Illegally Highlighting Challenges to Enforcement

Yesterday FDA announced that earlier this month it issued Warning Letters to four networks selling opioid drugs illegally online via 21 websites. Earlier this summer FDA had issued similar Warning letters to a total of 13 companies marketing opioid drugs illegally on about 70 websites. It is questionable if these measures are an effective deterrence … Read more

What’s All the Fuss About Number of 483s Issued in India and China?

About 80% of all active pharmaceutical ingredients (API) and two-thirds of drug products sold in the US are manufactured in India and China that together boast of about 1000 FDA-registered manufacturing sites. Also, manufacturers based in the two countries hold more generic drug approvals than any other country, including the United States. One can argue … Read more

FDA: Use Alternate Strategies to Include Data From “Interesting” Patients in Clinical Trials 

The enrollment criteria for most clinical trials exclude older or pediatric patients, patients with organ disfunctions, pregnant and lactating women, and patients with multiple chronic conditions. An FDA report released this week summarizes how data from such patient populations can be collected to support inclusion of these populations on the product labels.  Sponsors are reluctant … Read more

FDA Approval of a Contraceptive Mobile App Shows Why It is Not Worth it 

This week FDA approved the first mobile contraceptive app created by a Swedish startup. The app basically uses a calendar connected to temperature reading submitted by the users to calculate their menstrual cycle and predict more fertile days than others. There are several reasons why this approval may be both a gimmick and a significant … Read more

Mobile technologies in Clinical Trials: Detailed Roadmap from CTTI and FDA  

A report released last month by the Clinical Trial Transformation Initiative (CTTI), a joint venture of FDA and the Duke University, contends that all clinical trials should use mobile technologies to increase patient participation and retention, while reducing cost, increasing efficiency, and capturing real-time and real-world clinical data. The report acknowledges that the sponsors will … Read more

Got Milk! Not if You Ask FDA. 

FDA announced last week that it is planning to create restrictions on using the word “milk” to describe non-dairy products such as almond milk, soy milk, etc. citing that consumers are “hurt” when non-dairy products are called “Milk”. It is hard to argue over the frivolity of this FDA initiative. Non-dairy products that look and … Read more

FDA Commissioner’s Tweetorials: The New Age of FDA Advice Via Tweets 

Recently the FDA Commissioner, who is a prolific Tweeter, started Sunday-special tweets called the “Sundaytweetorials” to discuss broad issues. Last Sunday’s “tweetorial” included a series of 22 tweets discussing issues related to clinical trial design. The tweets discussed common strategic considerations for clinical trial design and related issues. Although there were no new announcements or … Read more

FDA Proposes Special Meetings to Discuss New Surrogate Endpoints 

This week FDA released a list of all surrogate endpoints used for approval of drugs and created a special meeting specifically to discuss creation of new surrogate endpoints. The list of surrogate endpoints includes more than 100 drug and biologic products approved by FDA over the last 10-15 years and cover practically all major indications. … Read more